Drug · CHEMBL1201585
TRASTUZUMAB
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. TRASTUZUMAB. Drugs and targets, record CHEMBL1201585. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1201585
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
- Herceptin, Herwenda, Herzuma, Kadcyla, Kanjinti, Ogivri, Ontruzant, Trastuzumab component of herceptin hylecta, Trastuzumab component of phesgo, Trazimera, Zercepac
- ChEMBL
- Other names
4D5V8, ABP 980, ABP-980, ABP980, Abp-980 (trastuzumab biosimilar), Bmab-200, Canhera, DMB-3111 (TRASTUZUMAB BIOSIMILAR), Dmb-3111, EG-12014, EG12014, Eg-12014 (trastuzumab biosimilar), Eg12014 trastuzumab biosimilar, HLX-02, Hercessi, Herzuma, Hlx 02, Hlx-02 trastuzumab biosimilar, Hlx02, Kanjinti, Ogivri, Ontruzant, Pf-05280014, R-597, RHUMABHER2, RO-0452317, RO0452317, Rhumab her2, SYD-977, SYD977, Sb-3 (trastuzumab biosimilar), Trastuzumab (herceptin), Trastuzumab anns, Trastuzumab beta, Trastuzumab biosimilar (abp-980), Trastuzumab biosimilar (amgen), Trastuzumab biosimilar (ct-p6), Trastuzumab biosimilar (pfizer), Trastuzumab biosimilar (sb-3), Trastuzumab dkst, Trastuzumab dttb, Trastuzumab pkrb, Trastuzumab qyyp, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-oysk, Trastuzumab-pfizer, Trastuzumab-pkrb, Trastuzumab-qyyp, Trastuzumab-strf, Trastuzumab-zzxf, Trazimera, Zercepac
- ChEMBL
- Open Targets' highest stage
- Approval, for 8 of its 94 diseases, from ATC, ClinicalTrials.gov, DailyMed, EMA Human Drugs, PMDA and TTD
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| ERBB2 | Receptor tyrosine-protein kinase erbB-2 | Receptor protein-tyrosine kinase erbB-2 inhibitor | INHIBITOR | https://conductscience.org/library/genes/2064 |
Source ChEMBL
Diseases94
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| breast cancer | Approval | ClinicalTrials.gov, DailyMed, PMDA and TTD | 745 | 728 | https://conductscience.org/library/drugs?q=MONDO_0007254 |
| gastric cancer | Approval | PMDA | 55 | 52 | https://conductscience.org/library/drugs?q=MONDO_0001056 |
| gastric adenocarcinoma | Approval | ClinicalTrials.gov, at phase 4 | 36 | 33 | https://conductscience.org/library/drugs?q=MONDO_0005036 |
| gastroesophageal junction adenocarcinoma | Phase 3 | ClinicalTrials.gov | 32 | 32 | https://conductscience.org/library/drugs?q=MONDO_0003219 |
| cancer | Approval | PMDA | 23 | 22 | https://conductscience.org/library/drugs?q=MONDO_0004992 |
| colorectal cancer | Phase 3 | ClinicalTrials.gov | 22 | 22 | https://conductscience.org/library/drugs?q=MONDO_0005575 |
| breast carcinoma | Approval | ClinicalTrials.gov and DailyMed | 10 | 9 | https://conductscience.org/library/drugs?q=MONDO_0004989 |
| esophageal adenocarcinoma | Phase 3 | ClinicalTrials.gov | 9 | 9 | https://conductscience.org/library/drugs?q=MONDO_0005028 |
| non-small cell lung carcinoma | Phase 2 | ClinicalTrials.gov | 9 | 9 | https://conductscience.org/library/drugs?q=MONDO_0005233 |
| biliary tract cancer | Phase 3 | ClinicalTrials.gov | 7 | 7 | https://conductscience.org/library/drugs?q=MONDO_0003060 |
1 to 10 of 94Source Open Targets
See all 94 diseasesTrials1,026
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 2 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 10 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00490139 | ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D | Phase 3 | 8,381 | 2014-08-18 | trastuzumab | Its name | ClinicalTrials.gov |
| NCT00045032 | Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer | Phase 3 | 5,099 | 2017-04-27 | trastuzumab | Its name | ClinicalTrials.gov |
| NCT01358877 | A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer | Phase 3 | 4,804 | 2018-01-05 | trastuzumab | Its name | ClinicalTrials.gov |
| NCT01275677 | Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer | Phase 3 | 3,270 | 2020-09-23 | trastuzumab | Its name | ClinicalTrials.gov |
| NCT00021255 | Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer | Phase 3 | 3,222 | 2016-11-15 | trastuzumab | Its name | ClinicalTrials.gov |
| NCT01566721 | A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer | Phase 3 | 2,577 | 2017-04-18 | trastuzumab | Its name | ClinicalTrials.gov |
| NCT00769379 | Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy | Phase 3 | 2,014 | 2022-02-23 | trastuzumab | Its name | ClinicalTrials.gov |
| NCT01966471 | A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer | Phase 3 | 1,846 | 2021-01-12 | trastuzumab | Its name | ClinicalTrials.gov |
| NCT01772472 | A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE) | Phase 3 | 1,486 | 2019-10-01 | trastuzumab | Its name | ClinicalTrials.gov |
| NCT01572038 | A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer | Phase 3 | 1,436 | 2020-09-25 | trastuzumab | Its name | ClinicalTrials.gov |
1 to 10 of 1,026
See all 1,026 trialsComparisons in its trials267
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy: deaths from any cause | 205 of 2,400 | 247 of 2,404 | 4,804 | NCT01358877 | Trial comparisons |
| Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy: serious adverse events | 792 of 2,364 | 686 of 2,405 | 4,769 | NCT01358877 | Trial comparisons |
| Arm I (Chemotherapy) vs Arm II (Chemotherapy, Trastuzumab): deaths from any cause | 48 of 1,622 | 61 of 1,628 | 3,250 | NCT01275677 | Trial comparisons |
| Arm I (Chemotherapy) vs Arm II (Chemotherapy, Trastuzumab): serious adverse events | 31 of 1,615 | 96 of 1,625 | 3,240 | NCT01275677 | Trial comparisons |
| Standard WBI vs WBI, Trastuzumab: deaths from any cause | 11 of 1,005 | 10 of 993 | 1,998 | NCT00769379 | Trial comparisons |
| Standard WBI vs WBI, Trastuzumab: serious adverse events | 3 of 998 | 9 of 990 | 1,988 | NCT00769379 | Trial comparisons |
| Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane vs Anthracycline Followed by Trastuzumab Emtansine and Pertuzumab: deaths from any cause | 45 of 926 | 55 of 912 | 1,838 | NCT01966471 | Trial comparisons |
| Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane vs Anthracycline Followed by Trastuzumab Emtansine and Pertuzumab: serious adverse events | 216 of 926 | 195 of 912 | 1,838 | NCT01966471 | Trial comparisons |
| Trastuzumab vs Trastuzumab Emtansine: deaths from any cause | 126 of 743 | 94 of 743 | 1,486 | NCT01772472 | Trial comparisons |
| Trastuzumab vs Trastuzumab Emtansine: Number of Participants With AEs and SAEs Leading to Death | 0 of 720 | 1 of 740 | 1,460 | NCT01772472 | Trial comparisons |
1 to 10 of 267
See all 267 comparisons in its trialsPapers from its trials692
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials3
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Picture Naming Test | 1 | 0 | ConductCognition |
| Stroop Color-Word Test | 1 | 0 | ConductCognition |
| Verbal Fluency | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1201585
GET https://conductscience.org/api/drugs/v1/CHEMBL1201585/diseases?page=2